Journal article
Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis
Abstract
ABSTRACT: Quadruplet regimens (anti-CD38 monoclonal antibodies [mAbs] with proteasome inhibitor [PI] and immunomodulatory drugs [IMiDs]) are increasingly being investigated in newly diagnosed multiple myeloma (NDMM). The objective of our study was to conduct a systematic review and meta-analysis to measure the efficacy and toxicity of quadruplet regimens used in NDMM. Embase, MEDLINE, Web of Science, Cochrane Library, clinical trial registries, …
Authors
Ebraheem MS; Chakraborty R; Rochwerg B; Visram A; Mohyuddin GR; Venner CP; Sandhu I; McCurdy A; Facon T; Mateos M-V
Journal
Blood Advances, Vol. 8, No. 23, pp. 5993–6002
Publisher
American Society of Hematology
Publication Date
December 10, 2024
DOI
10.1182/bloodadvances.2024014139
ISSN
2473-9529